AVLIN BARLOW IMAEDA, MD
Osteopathic Medicine in New Haven, CT
License number
Connecticut 041499
Category
Osteopathic Medicine
Type
Internal Medicine
License number
Connecticut 041499
Category
Osteopathic Medicine
Type
Gastroenterology
Address
Address
2
950 Campbell Ave Va Ct, New Haven, CT 06516
237 LANDON'S WAY, Guilford, CT 06437
237 LANDON'S WAY, Guilford, CT 06437
Phone
(203) 932-5711
(203) 937-3873 (Fax)
(203) 785-7998
(203) 785-6414 (Fax)
(203) 937-3873 (Fax)
(203) 785-7998
(203) 785-6414 (Fax)
Personal information
See more information about AVLIN BARLOW IMAEDA at radaris.comName
Address
Phone
237 Landons Way, Guilford, CT 06437
237 Landons Way, Guilford, CT 06437
Professional information
See more information about AVLIN BARLOW IMAEDA at trustoria.com
Dr. Avlin B Imaeda, West Haven CT - MD (Doctor of Medicine)
Dr. Avlin B Imaeda, West Haven CT - MD (Doctor of Medicine)
Specialties:
Gastroenterology
Address:
VA CONNECTICUT HEALTHCARE SYST
950 Campbell Ave, West Haven 06516
(203) 932-5711 (Phone), (203) 937-4935 (Fax)
950 Campbell Ave, West Haven 06516
(203) 932-5711 (Phone), (203) 937-4935 (Fax)
Certifications:
Gastroenterology, 2007, Internal Medicine, 2004
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
VA CONNECTICUT HEALTHCARE SYST
950 Campbell Ave, West Haven 06516
Yale - New Haven Hospital
20 York St, New Haven 06510
950 Campbell Ave, West Haven 06516
Yale - New Haven Hospital
20 York St, New Haven 06510
Education:
Medical School
A Einstein Col Med Yeshiva Univ
Graduated: 2000
A Einstein Col Med Yeshiva Univ
Graduated: 2000
Avlin Barlow Imaeda, West Haven CT
Avlin Barlow Imaeda, West Haven CT
Specialties:
Internist
Address:
950 Campbell Ave, West Haven, CT 06516
Education:
Doctor of Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Gastroenterology (Internal Medicine)
Compositions And Methods For Reducing Hepatotoxicity Associated With Drug Administration
Compositions And Methods For Reducing Hepatotoxicity Associated With Drug Administration
US Patent:
2010029, Nov 25, 2010
Filed:
Oct 20, 2008
Appl. No.:
12/734153
Inventors:
Wajahat Mehal - Guilford CT, US
Avlin Imaeda - Guilford CT, US
Avlin Imaeda - Guilford CT, US
Assignee:
YALE UNIVERSITY - New Haven CT
International Classification:
A61K 31/616, A61K 36/38, A61K 38/13, A61P 37/06, A61P 1/16
US Classification:
424730, 514165, 514 205
Abstract:
The present invention relates to the discovery that acetylsalicylic acid (ASA or aspirin), salicylic acid (SA) and related salicylate esters and their pharmaceutically acceptable salts, when coadministered in effective amounts with a drug or other bioactive agent which typically (in the absence of the salicylate compound) produces significant hepatotoxicity as a secondary indication, will substantially reduce or even eliminate such hepatotoxicity. Favorable therapeutic intervention results from the use of the present invention having the effect of reducing hepatotoxicity associated with the administration of certain drugs and other bioactive agents and in certain instances of allowing the administration of higher doses of a compound which, without the coadministration, would produce hepatotoxicity which limits or even negates the therapeutic value of the compound.
Compositions And Methods For Treating Or Inhibiting Liver Injury
Compositions And Methods For Treating Or Inhibiting Liver Injury
US Patent:
2012011, May 10, 2012
Filed:
Apr 16, 2010
Appl. No.:
13/264922
Inventors:
Wajahat Mehal - Guilford CT, US
Avlin Imaeda - Guilford CT, US
Avlin Imaeda - Guilford CT, US
Assignee:
Yale University - New Haven CT
International Classification:
A61K 31/60, A61P 1/16, A01N 1/02, A61K 31/702, A61K 38/22, A61K 31/616, A61P 29/00
US Classification:
514 97, 514159, 514 61, 435 11
Abstract:
The present invention relates to the discovery that acetylsalicylic acid (ASA or aspirin), salicylic acid (SA) and related salicylate esters and their pharmaceutically acceptable salts, when coadministered in effective amounts with a drug or other bioactive agent which typically (in the absence of the salicylate compound) produces significant hepatotoxicity as a secondary indication, will substantially reduce or even eliminate such hepatotoxicity. Favorable therapeutic intervention results from the use of the present invention having the effect of reducing hepatotoxicity associated with the administration of certain drugs and other bioactive agents and in certain instances of allowing the administration of higher doses of a compound which, without the coadministration, would produce hepatotoxicity which limits or even negates the therapeutic value of the compound. The invention also relates inter alia to methods of inhibiting or reducing the likelihood of liver injury secondary to hepatitis, cirrhosis and a number of other disease states and conditions and further may be used to reduce the likelihood of a patient at risk or treating a patient for inter alia hepatitis, cirrhosis, non-alcoholic fatty liver diseases (NAFLD), non-alcoholic steatohepatitis (NASH), cirrhosis and other disease states and conditions as otherwise described. Pharmaceutical compositions are also described.